Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. - Wikidata - awgldk - TriplyDB

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

http://www.wikidata.org/entity/Q34191995

about

Chemical probes of endocannabinoid metabolism The pharmacological landscape and therapeutic potential of serine hydrolases Reversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting Analgesics Rational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site Residues Preclinical Characterization of the FAAH Inhibitor JNJ-42165279 Latest advances in the discovery of fatty acid amide hydrolase inhibitors Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability Activity-based proteomic and metabolomic approaches for understanding metabolism α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.Discovery libraries targeting the major enzyme classes: the serine hydrolases.Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.How chemoproteomics can enable drug discovery and development Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.PET imaging of fatty acid amide hydrolase with [(18)F]DOPP in nonhuman primates.The metabolic serine hydrolases and their functions in mammalian physiology and disease.Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).PET radiopharmaceuticals for probing enzymes in the brain A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.Synthesis and Preliminary PET Imaging Studies of a FAAH Radiotracer ([¹¹C]MPPO) Based on α-Ketoheterocyclic Scaffold.Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.Design, synthesis, and characterization of α-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase Lipolytic proteomics.11CO2 fixation: a renaissance in PET radiochemistry.Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids.Lysine-Targeting Covalent Inhibitors.Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers

P2860

Q26863202-62069E21-B5A1-427B-A59C-FBB64B783820 Q26995817-DF3AC232-C475-4054-B8F9-FB9BCC6E9BC5 Q27667312-0F103EBB-7869-448A-A355-F2F37813E037 Q27677344-AF260984-42F6-4EDB-9BC4-34B5FA11F45B Q28271553-1756CB5F-8F8D-419E-B67A-7ADA4FD982E7 Q28287173-F4E984F8-DD53-47ED-B658-7F78A213C93D Q28300390-5C334C22-E4E9-457D-87C1-19181AF2CB2E Q28480988-3A929491-4326-457E-BCB3-3737732BE2D5 Q30405653-5F5FCEB1-2299-4396-AD22-6D3BADF155FE Q33644120-FBC2AA27-E058-4C4C-A1B0-F122E375E967 Q33781776-430B40D8-4309-4B63-BB65-4AB63FB4EA6B Q34027721-31F2BB13-44DB-4D59-A85A-5349A3B5F584 Q34029257-78DBB213-C0EB-44EF-8152-63D5234AB144 Q34036280-5B791A6A-5E3E-4F7D-8C7B-801AC6611C25 Q34041284-1EC1A217-458F-4A2A-B77F-9048437D9F8E Q34143272-EFBE26F6-3792-4BE2-8B29-273472B9B64F Q34179408-AFAD23FD-D87B-4CF8-860F-95040EC9C26D Q34452685-ECE88E82-67A5-4803-B9A8-E00F954CA749 Q34473739-73FBDDB8-5FE6-441E-98B8-4C252915A499 Q35333042-98044268-6DE0-4489-89BE-5F4177E7691C Q35660108-5D7D05A3-2893-4A24-8AA3-9E57FE37999F Q36254356-781A81F7-DF8D-409E-99C4-088B715917E3 Q36727793-02F76612-2BA2-4755-BC86-27F4E4AC3C4B Q36769219-C67F7747-3945-4B5D-99EA-3BA6F90B3A3E Q36823364-B2F45C4E-694B-4F3C-9918-B3CD155BE8A9 Q36926261-3A812070-A2DC-4C62-A7BB-0FB3C01C3BCE Q37082114-789F8871-9F05-4740-B67C-F3B3EB1A76CA Q37613654-8B5A99B6-163A-4A71-9B5C-01F60FB36011 Q37990875-9B0693B5-E2B2-4757-AA73-0380625352A0 Q38106855-D0ACEBA8-BB53-4166-BC24-1EF86941B9C0 Q38170338-0EB063D1-552D-4C2E-B035-F4F5BC1A2CFE Q38185075-1E7C0D68-43BE-4BA6-93F2-B948E4E907D2 Q38635726-794DB142-7F35-4A51-BDA6-9D3FF6554804 Q39694177-9506CB6C-897C-403D-9B42-95F943FB63CD Q39736130-EC1BF508-7A3C-40CE-B830-EC3997C46F64 Q41785885-294AA9DB-F07E-421B-ACED-638C46B6F4C1 Q41907633-7357F51F-149E-4EEB-B167-A90E5AD333E9 Q41971391-AFF427F1-6322-4BCF-AB22-7588F5C37596 Q42156717-5D68B14A-3779-4981-B1A4-9F1304E0CB65 Q42232533-AF96E952-7ACF-484C-8398-366BFA328C15

P2860

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

http://www.wikidata.org/entity/Q34191995

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@ast

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@en

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@nl

type

label

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@ast

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@en

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@nl

prefLabel

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@ast

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@en

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@nl

P1433

Q34191995-6850ED24-82BF-4D4A-8E05-3D323C8CFC07

P1476

Q34191995-6775DE60-EDA8-4FD0-B936-516DC07A7309

P2093

Q34191995-1EDAEE71-7892-436E-9C7C-FCE6AA286E87

Q34191995-264875B8-8C50-457A-8ACF-08246E1F915E

Q34191995-4214B195-B43A-473F-A456-A8EE5C5F2305

Q34191995-638EB51F-A2A5-4978-9E80-88C5CD78F050

Q34191995-68547CA4-1399-4A58-9F6E-564DACD6AFBF

Q34191995-6FB891A7-3A8E-41CC-B352-780D75FB1694

Q34191995-71DA9C4A-ECB3-47D7-B87B-36A746AAFAF0

Q34191995-7B55F823-72FF-40F6-A779-33F517816017

Q34191995-8432FC37-54D2-407E-8D9F-65A6A4C84EC6

Q34191995-92ECCAE3-1142-47CE-8829-2D2C9F89DE6D

P2860

Q34191995-098AA46F-AA7B-4E52-97B5-22FCEB9C0BC1

Q34191995-1C184DEC-50ED-4D18-9F7F-4A6472F5634C

Q34191995-21D43927-5D70-4FDD-95DF-F1AA4B507B1A

Q34191995-220377F5-ABA3-41FE-B7AF-03DD4142021C

Q34191995-28B72828-18E1-4AE2-BE48-5BE82E8A7D0A

Q34191995-2EEFBE96-6B52-42F7-9760-0C2BC21C85E0

Q34191995-3EE6281A-CF7D-41D3-BA10-8CCE6C0C91AA

Q34191995-3F0E42DE-B46B-4F68-951F-8D90DDDC82BD

Q34191995-438E3735-9EDB-4D4A-A582-754C512EA344

Q34191995-66933DDD-3616-48DD-AF2E-25E1B1AD51F7

P304

Q34191995-CDAAFB78-AC48-4F74-9B56-4FA6D33A2649

P31

Q34191995-58462244-DB8E-4267-923B-724F9393CFCE

P356

Q34191995-C5CD48E5-447E-42C8-A40D-B6A0F19D1B1A

P433

Q34191995-6801B2AE-1D4E-4159-B56B-98C1C1EAEEC2

P478

Q34191995-DC8AD182-DC5F-408A-8D93-D6458E834F9B

P50

Q34191995-6F0482C9-92DF-49CF-9815-376837C31393

P577

Q34191995-06E995C9-75ED-4A79-B5B8-35D690C2A792

P5875

Q34191995-A3CFE000-52C4-4755-A791-1EAB531F33D7

P698

Q34191995-2C8D924C-5394-4E46-AE56-153DA32AE767

P932

Q34191995-1C9F252B-952F-4416-BD9F-4693D84BD269

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Discovery of PF-04457845: A Hi ...... Selective Urea FAAH Inhibitor.

@en

P2093

Cory Stiff

http://www.w3.org/2001/XMLSchema#string

David Beidler

http://www.w3.org/2001/XMLSchema#string

David T Dudley

http://www.w3.org/2001/XMLSchema#string

Douglas S Johnson

http://www.w3.org/2001/XMLSchema#string

Kay Ahn

http://www.w3.org/2001/XMLSchema#string

Lorraine K Fay

http://www.w3.org/2001/XMLSchema#string

Mark Morris

http://www.w3.org/2001/XMLSchema#string

Marya B Liimatta

http://www.w3.org/2001/XMLSchema#string

Nalini Sadagopan

http://www.w3.org/2001/XMLSchema#string

Sarah E Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

Structure-guided inhibitor design for human FAAH by interspecies active site conversion

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

Binding and Inactivation Mechanism of a Humanized Fatty Acid Amide Hydrolase by α-Ketoheterocycle Inhibitors Revealed from Cocrystal Structures

Crystal Structure of Fatty Acid Amide Hydrolase Bound to the Carbamate Inhibitor URB597: Discovery of a Deacylating Water Molecule and Insight into Enzyme Inactivation

Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism

Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies

P304

91-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML100190T

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Cravatt III

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51213147

http://www.w3.org/2001/XMLSchema#string

P698

21666860

http://www.w3.org/2001/XMLSchema#string

P932

3109749

http://www.w3.org/2001/XMLSchema#string